PSAB
MCID: PLY068
MIFTS: 44

Polysubstance Abuse (PSAB)

Categories: Genetic diseases

Aliases & Classifications for Polysubstance Abuse

MalaCards integrated aliases for Polysubstance Abuse:

Name: Polysubstance Abuse 57 55 72
Polysubstance Abuse, Susceptibility to 57 29 40
Drug Addiction 57 55
Drug Addiction, Susceptibility to 57
Drug Dependence 72
Psab 57

Classifications:



External Ids:

OMIM 57 606581
UMLS 72 C0747752 C1510472

Summaries for Polysubstance Abuse

MalaCards based summary : Polysubstance Abuse, also known as polysubstance abuse, susceptibility to, is related to drug dependence and pain agnosia. An important gene associated with Polysubstance Abuse is FAAH (Fatty Acid Amide Hydrolase), and among its related pathways/superpathways are Circadian entrainment and Monoamine GPCRs. The drugs tannic acid and Benzocaine have been mentioned in the context of this disorder. Affiliated tissues include brain, testes and bone, and related phenotypes are behavior/neurological and homeostasis/metabolism

More information from OMIM: 606581

Related Diseases for Polysubstance Abuse

Diseases related to Polysubstance Abuse via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 398)
# Related Disease Score Top Affiliating Genes
1 drug dependence 30.4 DRD3 DRD2 CNR1
2 pain agnosia 30.3 FAAH CNR1
3 pathological gambling 30.1 DRD3 DRD2
4 cocaine dependence 30.0 DRD3 DRD2
5 substance abuse 30.0 DRD3 DRD2 COMT
6 opiate dependence 29.9 DRD3 DRD2
7 bruxism 29.8 DRD3 DRD2
8 opioid addiction 29.6 DRD2 COMT
9 impulse control disorder 29.6 DRD3 DRD2
10 traumatic brain injury 29.6 DRD2 COMT
11 brain injury 29.6 DRD2 COMT
12 personality disorder 29.6 DRD2 COMT
13 anxiety 29.5 COMT CNR1
14 substance dependence 29.4 DRD3 DRD2 CNR1
15 tobacco addiction 29.2 DRD2 COMT
16 eating disorder 29.2 DRD2 COMT CNR1
17 psychotic disorder 29.2 DRD3 DRD2 COMT
18 movement disease 29.2 DRD3 DRD2
19 alexithymia 29.2 DRD2 COMT
20 body mass index quantitative trait locus 11 29.1 FAAH DRD2 CNR1
21 antisocial personality disorder 29.1 DRD2 COMT
22 mood disorder 29.0 DRD3 DRD2 COMT
23 attention deficit-hyperactivity disorder 28.9 DRD3 DRD2 COMT
24 obsessive-compulsive disorder 28.9 DRD3 DRD2 COMT
25 major depressive disorder 28.8 DRD3 DRD2 COMT
26 bipolar disorder 28.7 DRD3 DRD2 COMT
27 post-traumatic stress disorder 28.4 FAAH DRD2 COMT CNR1
28 migraine with or without aura 1 28.3 DRD3 DRD2 COMT CNR1
29 gilles de la tourette syndrome 28.2 DRD2 COMT
30 disease of mental health 28.2 DRD3 DRD2 COMT CNR1
31 alcohol dependence 28.0 FAAH DRD3 DRD2 COMT CNR1
32 schizophrenia 27.8 DRD3 DRD2 COMT CNR1
33 endocarditis 10.8
34 infective endocarditis 10.6
35 helix syndrome 10.6
36 immune deficiency disease 10.5
37 viral hepatitis 10.5
38 human immunodeficiency virus type 1 10.5
39 hepatitis c 10.5
40 acquired immunodeficiency syndrome 10.5
41 hepatitis c virus 10.4
42 hepatitis 10.4
43 hepatitis b 10.4
44 withdrawal disorder 10.4
45 alcohol use disorder 10.4
46 hepatitis a 10.4
47 candidiasis 10.3
48 kaposi sarcoma 10.3
49 osteomyelitis 10.3
50 liver disease 10.3

Graphical network of the top 20 diseases related to Polysubstance Abuse:



Diseases related to Polysubstance Abuse

Symptoms & Phenotypes for Polysubstance Abuse

Clinical features from OMIM:

606581

MGI Mouse Phenotypes related to Polysubstance Abuse:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 9.55 CNR1 COMT DRD2 DRD3 FAAH
2 homeostasis/metabolism MP:0005376 9.35 CNR1 COMT DRD2 DRD3 FAAH
3 nervous system MP:0003631 9.02 CNR1 COMT DRD2 DRD3 FAAH

Drugs & Therapeutics for Polysubstance Abuse

Drugs for Polysubstance Abuse (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 288)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
tannic acid Approved Phase 4 1401-55-4
2
Benzocaine Approved, Investigational Phase 4 94-09-7, 1994-09-7 2337
3
Cisatracurium Approved Phase 4 96946-41-7
4
Sufentanil Approved, Investigational Phase 4 56030-54-7 41693
5
Dexmedetomidine Approved, Vet_approved Phase 4 113775-47-6 68602 5311068
6
Aripiprazole Approved, Investigational Phase 4 129722-12-9 60795
7
Didanosine Approved Phase 4 69655-05-6 50599
8
Lamivudine Approved, Investigational Phase 4 134678-17-4 60825
9
Efavirenz Approved, Investigational Phase 4 154598-52-4 64139
10
Zidovudine Approved Phase 4 30516-87-1 35370
11
Tacrolimus Approved, Investigational Phase 4 104987-11-3 445643 439492 6473866
12
Ketamine Approved, Vet_approved Phase 4 6740-88-1 3821
13
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
14
Acetaminophen Approved Phase 4 103-90-2 1983
15
Tramadol Approved, Investigational Phase 4 27203-92-5 33741
16
Methadone Approved, Illicit Phase 4 76-99-3 4095
17
Oxytocin Approved, Vet_approved Phase 4 50-56-6 439302 53477758
18 Dexketoprofen trometamol Phase 4
19 Neuromuscular Agents Phase 4
20 Neuromuscular Blocking Agents Phase 4
21 Immunologic Factors Phase 4
22 Antiviral Agents Phase 4
23 Antimetabolites Phase 4
24 Serotonin Receptor Agonists Phase 4
25 Serotonin Antagonists Phase 4
26 Serotonin Agents Phase 4
27 Cytochrome P-450 CYP3A Inducers Phase 4
28 Cytochrome P-450 Enzyme Inducers Phase 4
29 Serotonin 5-HT2 Receptor Antagonists Phase 4
30 Serotonin 5-HT1 Receptor Agonists Phase 4
31 Dopamine D2 Receptor Antagonists Phase 4
32 Anti-Retroviral Agents Phase 4
33 Cytochrome P-450 Enzyme Inhibitors Phase 4
34 Cytochrome P-450 CYP2C9 Inhibitors Phase 4
35 Nucleic Acid Synthesis Inhibitors Phase 4
36 Cytochrome P-450 CYP2C19 Inhibitors Phase 4
37 Reverse Transcriptase Inhibitors Phase 4
38 Anti-HIV Agents Phase 4
39 Immunosuppressive Agents Phase 4
40 Calcineurin Inhibitors Phase 4
41 Antiparasitic Agents Phase 4
42 Antiprotozoal Agents Phase 4
43 Benzonidazole Phase 4
44 Anti-Inflammatory Agents Phase 4
45 Pharmaceutical Solutions Phase 4
46 Excitatory Amino Acid Antagonists Phase 4
47 Excitatory Amino Acids Phase 4
48 Anesthetics, General Phase 4
49 Anesthetics, Intravenous Phase 4
50 Anesthetics, Dissociative Phase 4

Interventional clinical trials:

(show top 50) (show all 273)
# Name Status NCT ID Phase Drugs
1 An Evaluation of Innovative Methods for Integrating Buprenorphine Opioid Treatment in HIV Primary Care Settings Unknown status NCT00124358 Phase 4 Buprenorphine
2 Intravenous Paracetamol Versus Intravenous Dexketoprofen in Patients Presented With Dysmenorrhea in Emergency Department Unknown status NCT02373514 Phase 4 Paracetamol;Dexketoprofen
3 The Efficacy and Optimal Dose of Sufentanil in Patient Controlled Analgesia After Moderate Surgery Unknown status NCT02503826 Phase 4 Sufentanil;Sufentanil;Sufentanil;Midazolam;propofol;cisatracurium
4 Clinical Trial: Esomeprazole Plus Alginate vs. Esomeprazole Alone for Treatment of Nighttime Reflux Symptom and GERD-related Sleep Disturbances in Patients With Erosive GERD Unknown status NCT02277886 Phase 4 sodium alginate;esomeprazole
5 Integration of Buprenorphine Into HIV Clinical Settings - Primary Care Model (PCM) Completed NCT00798538 Phase 4
6 On-Site Addiction Treatment With Buprenorphine in HIV Clinical Care Settings Completed NCT00317460 Phase 4
7 A Randomized Controlled Trial Comparing Buprenorphine and Methadone for Opioid Dependent Chronic Pain Patients Completed NCT00879996 Phase 4 Methadone;Buprenorphine/naloxone
8 Drug Contextual Conditioning With in Humans: Causes and Consequences Completed NCT03075501 Phase 4 Stimulant or sedative;Placebo
9 Target-controlled Infusion vs Patient-controlled Sedation With Propofol in ERCP. A Randomized Prospective Clinical Trial Completed NCT01072435 Phase 4
10 Dexmedetomidine vs Placebo in ERCP Sedation.A Randomized Pilot Study Completed NCT01070680 Phase 4 Precedex;sodium chlorid 0,9%
11 Project STRIDE2 - Seek/Test/Retain: PLWHA and Opioid Users in Washington, DC Completed NCT03583138 Phase 4 buprenorphine
12 Health Services Research: Extended Release Naltrexone for Opioid-Dependent Youth Completed NCT01843023 Phase 4 Extended Release Naltrexone;Buprenorphine
13 Intensive Outpatient v. Outpatient Treatment With Buprenorphine Among African Americans Completed NCT01096550 Phase 4
14 Effect of Dexmedetomidine on Mortality, Duration of Mechanical Ventilation and Multi-organ Function in Sepsis Patients Under Lighter Sedation by Randomized Control Trial Completed NCT01760967 Phase 4 Dexmedetomidine
15 Aripiprazole (Abilify) Therapy for Reducing Comorbid Substance Abuse Completed NCT00208169 Phase 4 Aripiprazole
16 A Multicenter, Randomized, Open Label, Clinical Trial Comparing a QD Regimen of Didanosine, Lamivudine and Efavirenz With a Standard BID Regimen of Zidovudine, Lamivudine and Efavirenz in the Starting Treatment of Human Immunodeficiency Virus Infection (GESIDA 39/03) Completed NCT00256828 Phase 4 didanosine + lamivudine + efavirenz
17 Transcranial Direct Current Stimulation for Treatment of Childhood Pharmacoresistant Lennox-Gastaut Syndrome, A Pilot Study Completed NCT02731300 Phase 4
18 Randomized Therapeutic Study of a Treatment by Tacrolimus Adapted or Not According to the Genotype of the Cytochrome P450 3A5 After Renal Transplantation Completed NCT00552201 Phase 4 Tacrolimus
19 Optimization of Sampling Procedure for PCR Technique to Assess Parasitological Response for Patients With Chronic Chagas Disease Treated With Benznidazole in Aiquile, Bolivia Completed NCT01678599 Phase 4 Benznidazole
20 Effects of Intranasal Oxytocin on Cigarette Smoking Recruiting NCT02595749 Phase 4 Oxytocin;Placebo
21 Intravenous Lidocaine for Perioperative and Postoperative Analgesia Recruiting NCT03921567 Phase 4 Lidocaine Hydrochloride;Lidocaine Hydrochloride and Ketamine;Placebo
22 Neuroplasticity Following Theta-Burst Stimulation in Cocaine Use Recruiting NCT02927236 Phase 4
23 Comparing Efficiencies of Intravenous Paracetamol and Intravenous Tramadol in Patients With Primary Dysmenorrhea Presented in Emergency Department Not yet recruiting NCT03509740 Phase 4 tramadol;paracetamol
24 A Prospective, Sixteen-Week, Double-Blind, Placebo-Controlled, Trial of Seroquel in Combination With Treatment as Usual in Patients With GAD and Remitted Comorbid Opiate Dependence Terminated NCT00668265 Phase 4 Quetiapine
25 Oxytocin and Cognitive Behavioral Therapy in Drug Dependence Terminated NCT00975416 Phase 4 Intranasal Oxytocin;Placebo
26 A Randomized Controlled Trial Testing Buprenorphine as a Treatment in Opiate Dependent Pain Patients Terminated NCT00552578 Phase 4 buprenorphine/naloxone;buprenorphine/naloxone
27 Dopamine Beta-hydroxylase Inhibition Induced Blunting of Dopaminergic Response to Psychostimulant Administration. A PET Exploration of the Mechanism of Action of a New Therapeutic Strategy in Cocaine Addicts Withdrawn NCT02134002 Phase 4 Disulfiram;Placebo
28 A Randomized Controlled Trial Comparing Buprenorphine/Naloxone With Naltrexone for Treatment in Opioid Dependent Adolescents and Young Adults Withdrawn NCT01015066 Phase 4 Buprenorphine/naloxone;Naltrexone
29 AN OPEN-LABEL TRIAL OF REDUCED- DOSE PYLERA (BISMUTH, METRONIDAZOLE, TETRACYCLINE), AMOXICILLIN, AND ESOMEPRAZOLE IN THE TREATMENT OF HELICOBACTER PYLORI INFECTION Withdrawn NCT02045251 Phase 4 Pylera based reduced regimen
30 Comparing Acute and Continuous Drug Abuse Treatment: A Randomized Clinical Trial Unknown status NCT01003496 Phase 3
31 A Pilot Study to Evaluate the Effect of Forsteo (Teriparatide, 1-34-rh-PTH) in Anorexia Nervosa Patients With Low Bone Mineral Density and Increased Bone Fagility (FAN-Trial) Unknown status NCT01801397 Phase 3 osteoanabolic therapy
32 An Open-label Study of Oral Paliparidone for the Treatment of Patients With Co-occurring Opioid and Amphetamine-type Stimulant Dependence Unknown status NCT02541513 Phase 3 paliparidone
33 Effectiveness of Adjuvant Radiotherapy in Patients With Oropharyngeal and Floor of Mouth Squamous Cell Carcinoma and Concomitant Histological Verification of Singular Ipsilateral Cervical Lymph Node Metastasis (pN1-state) Unknown status NCT00964977 Phase 3
34 Job Seekers Training for Patients With Drug Dependence Completed NCT00102362 Phase 3
35 The Role of Sleep in the Treatment of Cannabis Use Disorders Completed NCT01685073 Phase 2, Phase 3 Zolpidem extended-release
36 Treating the Partners of Drug Using Pregnant Women: Stage II Completed NCT00496990 Phase 2, Phase 3
37 Cocaine/Crack Dependence: A Study of the Possible Reduction of Compulsion Under the Use of Biperiden Completed NCT01251393 Phase 3 Biperiden;Placebo
38 Linkage of Alcohol Abusers to Primary Care Completed NCT00278447 Phase 3
39 SEDATIVE PREMEDICATION: EFFICACY ON PATIENT EXPERIENCE Completed NCT01901003 Phase 3 Lorazepam;Placebo (microcrystalline celluloses)
40 Recovery Housing For Drug Dependent Pregnant Women Completed NCT00497302 Phase 2, Phase 3
41 Extended Tobacco Dependence Intervention in Buprenorphine Treatment Completed NCT01350011 Phase 3
42 BOSCOT: A Randomised Control Trial of Cognitive Behavioural Therapy Plus Treatment as Usual Versus Treatment as Usual in the Treatment of Borderline Personality Disorder Completed NCT00538135 Phase 3
43 Preventing Drug Use in Low Income Clinic Populations Completed NCT01942876 Phase 2, Phase 3
44 Reinforcing Effects of Intravenous Buprenorphine Versus Buprenorphine/Naloxone in Buprenorphine-maintained Intravenous Drug Users (P05207) Completed NCT00710385 Phase 3 Heroin;Naloxone;Low Bup Dose;High Bup Dose;Low Bup/Nal Dose;High Bup/Nal Dose;Placebo (PCB)
45 Effect of Mesalazine on Low Grade Mucosal Inflammation in Irritable Bowel Syndrome. A Pilot Double Blind Placebo Controlled Study. Completed NCT00774007 Phase 2, Phase 3 mesalazine;placebo
46 The Influence of Age on Bispectral Index Associated With Propofol-induced Sedation Completed NCT02046720 Phase 3 Propofol induced sedation
47 A Multicenter, Double-blind, Randomized, Placebo-controlled Study of Weight-Reduction and/or Low Sodium Diet Plus Acetazolamide vs Diet Plus Placebo in Subjects With Idiopathic Intracranial Hypertension With Mild Visual Loss Completed NCT01003639 Phase 2, Phase 3 Acetazolamide;Placebo
48 The Impact of Concomitant Ultra Low Dose Infusion Naloxone and Therapeutic Infusion Opioid on Opioid Requirements in Pediatric ICU Patients Completed NCT00286052 Phase 3 Low Dose Naloxone
49 Child and Adolescent Trial for Cardiovascular Health (CATCH) Completed NCT00000467 Phase 3
50 The Prevention of Post Operative Cognitive Dysfunction by Ketamine: a Prospective Multicenter Randomized Blinded Placebo-controlled Trial in Elderly Patients Undergoing Elective Orthopaedic Surgery Recruiting NCT02892916 Phase 3 Ketamine;Placebo

Search NIH Clinical Center for Polysubstance Abuse

Genetic Tests for Polysubstance Abuse

Genetic tests related to Polysubstance Abuse:

# Genetic test Affiliating Genes
1 Polysubstance Abuse, Susceptibility to 29 FAAH

Anatomical Context for Polysubstance Abuse

MalaCards organs/tissues related to Polysubstance Abuse:

41
Brain, Testes, Bone, Liver, Cortex, Prefrontal Cortex, Lymph Node

Publications for Polysubstance Abuse

Articles related to Polysubstance Abuse:

(show top 50) (show all 298)
# Title Authors PMID Year
1
Polysubstance abuse-vulnerability genes: genome scans for association, using 1,004 subjects and 1,494 single-nucleotide polymorphisms. 38 8
11704927 2001
2
Association of a functional FAAH polymorphism with methamphetamine-induced symptoms and dependence in a Malaysian population. 8
23556448 2013
3
The fatty acid amide hydrolase 385 A/A (P129T) variant: haplotype analysis of an ancient missense mutation and validation of risk for drug addiction. 8
16972078 2006
4
A functional glutathione S-transferase P1 gene polymorphism is associated with methamphetamine-induced psychosis in Japanese population. 8
15729709 2005
5
A missense mutation in human fatty acid amide hydrolase associated with problem drug use. 8
12060782 2002
6
Association study of the CNR1 gene exon 3 alternative promoter region polymorphisms and substance dependence. 9 38
16741937 2006
7
Human cannabinoid receptor 1: 5' exons, candidate regulatory regions, polymorphisms, haplotypes and association with polysubstance abuse. 9 38
15289816 2004
8
Confirmation of an excess of the high enzyme activity COMT val allele in heroin addicts in a family-based haplotype relative risk study. 9 38
11054766 2000
9
Prolonged P300 latency in a neuropsychiatric population with the D2 dopamine receptor A1 allele. 9 38
7704037 1994
10
Substance abuse vulnerability and D2 receptor genes. 9 38
7681236 1993
11
Gluteal compartment syndrome following alcohol intoxication: Case report and literature review. 38
31360451 2019
12
Marijuana Use in Pregnancy: A Review. 38
31343707 2019
13
Locomotor sensitization in male Sprague-Dawley rats following repeated concurrent treatment with 4-methylmethcathinone and 3,4-methylenedioxymethamphetamine. 38
31268871 2019
14
A Call for Caution in Prescribing Gabapentin to Individuals With Concurrent Polysubstance Abuse: A Case Report. 38
31291212 2019
15
Commentary on "A Call for Caution in Prescribing Gabapentin to Individuals with Concurrent Polysubstance Abuse: A Case Report". 38
31291213 2019
16
Therapeutic challenges for concurrent ethanol and nicotine consumption: naltrexone and varenicline fail to alter simultaneous ethanol and nicotine intake by female alcohol-preferring (P) rats. 38
30758525 2019
17
Retrospective Review of Need for Delayed Naloxone or Oxygen in Emergency Department Patients Receiving Naloxone for Heroin Reversal. 38
30961922 2019
18
Undifferentiated Shock and Extreme Elevation of Procalcitonin Related to Kratom Use. 38
31160844 2019
19
A Fatality Involving Furanylfentanyl and MMMP, with Presumptive Identification of Three MMMP Metabolites in Urine. 38
30566582 2019
20
Decompression Hemicraniectomy for Refractory Intracranial Hypertension in Reversible Cerebral Vasoconstriction Syndrome. 38
31001036 2019
21
Microsurgical Clip Reconstruction of a Ruptured Dissecting PICA Aneurysm: a 2D Operative Video. 38
30872198 2019
22
Effect of Bile Duct Ligation-induced Liver Dysfunction on Methamphetamine Pharmacokinetics and Locomotor Activity in Rats. 38
31329536 2019
23
Osteopathic Physical Exam Findings in Chronic Hepatitis C: A Case Study. 38
30937237 2019
24
Snow and Reindeer: Large Tricuspid Valve Mobile Vegetation. 38
30504520 2018
25
Hydrops and fetal hypoplastic left heart: An unexpected improvement after cessation of maternal polysubstance abuse. 38
30194993 2018
26
Ephenidine, diphenidine, and methoxphenidine complications reported to the French Addictovigilance Network. 38
29956843 2018
27
Exploring the association between initial serum alcohol concentration and polysubstance use: More than a simple "gateway drug" effect? 38
30662866 2018
28
Acute Liver Injury Induced by Synthetic Cannabinoid Abuse. 38
30416907 2018
29
Dislocation rate increases with bariatric surgery before total hip arthroplasty. 38
29756506 2018
30
Patterns and sociodemographic characteristics of substance abuse in Al Qassim, Saudi Arabia: a retrospective study at a psychiatric rehabilitation center. 38
30284986 2018
31
Dexmedetomidine-induced fever and delirium: A case report. 38
29574851 2018
32
Acute progressive paraplegia in heroin-associated myelopathy. 38
29483006 2018
33
Bradycardia and Syncope in a Patient Presenting With Loperamide Abuse. 38
30013863 2018
34
Nicotine as a discriminative stimulus for ethanol use. 38
29179044 2018
35
Unexplained Portal Gas in a Patient with an Esophageal Ulcer. 38
30643653 2018
36
Cave diving for a diagnosis: Disseminated histoplasmosis in the immunocompromised. 38
29942759 2018
37
Prevalence of Polysubstance Abuse and Dual Diagnosis in Patients Admitted to Alcohol Rehabilitation Units for Alcohol-Related Problems in Italy: Changes in 15 Years. 38
29016981 2017
38
Thrombotic thrombocytopenic purpura possibly triggered by Graves' disease. 38
29744115 2017
39
Possible Reversible Cerebral Vasoconstriction Syndrome Associated with Eucalyptus: Case Report. 38
29163745 2017
40
Autopsy-proven Mirtazapine Withdrawal-induced Mania/Hypomania Associated with Sudden Death. 38
29472753 2017
41
Distinct cognitive performance and patterns of drug use among early and late onset cocaine users. 38
28475942 2017
42
Two Fatal Intoxications Involving 3-Methoxyphencyclidine. 38
28830118 2017
43
Levamisole-Induced Leukocytoclastic Vasculitis with Negative Serology in a Cocaine User. 38
28592788 2017
44
Evaluation of drug use and medication compliance in adolescents admitted to a psychiatric facility from the pediatric emergency department. 38
28622813 2017
45
Waiting time variation in Early Intervention Psychosis services: longitudinal evidence from the SEPEA naturalistic cohort study. 38
28213813 2017
46
Oxymorphone Induced Thrombotic Microangiopathy Mimicking Atypical Haemolytic Uremic Syndrome. 38
28718268 2017
47
Interactions between nicotine and drugs of abuse: a review of preclinical findings. 38
27589579 2017
48
Gonococcal Endocarditis: The Gift That Stops Giving! An Uncommon Presentation of a Common Disease. 38
28414664 2017
49
Cognitive Impairment and Tramadol Dependence. 38
27918316 2017
50
Corrigendum to "Subdural Empyema Complicating Bacterial Meningitis: A Challenging Diagnosis in a Patient with Polysubstance Abuse". 38
29348757 2017

Variations for Polysubstance Abuse

Expression for Polysubstance Abuse

Search GEO for disease gene expression data for Polysubstance Abuse.

Pathways for Polysubstance Abuse

GO Terms for Polysubstance Abuse

Cellular components related to Polysubstance Abuse according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 axon GO:0030424 9.43 DRD2 COMT CNR1
2 integral component of presynaptic membrane GO:0099056 9.37 DRD2 CNR1
3 glutamatergic synapse GO:0098978 9.33 DRD3 DRD2 CNR1
4 endocytic vesicle GO:0030139 9.32 DRD3 DRD2
5 dopaminergic synapse GO:0098691 8.96 DRD3 DRD2
6 GABA-ergic synapse GO:0098982 8.8 DRD3 DRD2 CNR1

Biological processes related to Polysubstance Abuse according to GeneCards Suite gene sharing:

(show all 34)
# Name GO ID Score Top Affiliating Genes
1 response to drug GO:0042493 9.8 DRD3 DRD2 COMT
2 response to ethanol GO:0045471 9.69 DRD3 DRD2 CNR1
3 locomotory behavior GO:0007626 9.66 DRD3 DRD2
4 regulation of lipid metabolic process GO:0019216 9.66 DRD3 CNR1
5 learning GO:0007612 9.65 DRD3 COMT
6 learning or memory GO:0007611 9.65 DRD3 CNR1
7 negative regulation of protein kinase B signaling GO:0051898 9.65 DRD3 DRD2
8 circadian regulation of gene expression GO:0032922 9.64 DRD3 DRD2
9 visual learning GO:0008542 9.64 DRD3 DRD2
10 response to nicotine GO:0035094 9.63 DRD2 CNR1
11 positive regulation of cytokinesis GO:0032467 9.63 DRD3 DRD2
12 response to amphetamine GO:0001975 9.62 DRD3 DRD2
13 arachidonic acid secretion GO:0050482 9.61 DRD3 DRD2
14 behavioral response to cocaine GO:0048148 9.61 DRD3 DRD2
15 adenylate cyclase-activating adrenergic receptor signaling pathway GO:0071880 9.6 DRD3 DRD2
16 synaptic transmission, dopaminergic GO:0001963 9.59 DRD3 DRD2
17 negative regulation of protein secretion GO:0050709 9.58 DRD3 DRD2
18 dopamine receptor signaling pathway GO:0007212 9.58 DRD3 DRD2
19 prepulse inhibition GO:0060134 9.57 DRD3 DRD2
20 regulation of synaptic transmission, GABAergic GO:0032228 9.56 DRD2 CNR1
21 positive regulation of renal sodium excretion GO:0035815 9.55 DRD3 DRD2
22 G protein-coupled receptor internalization GO:0002031 9.54 DRD3 DRD2
23 adenylate cyclase-inhibiting dopamine receptor signaling pathway GO:0007195 9.52 DRD3 DRD2
24 adenylate cyclase-modulating G protein-coupled receptor signaling pathway GO:0007188 9.5 DRD3 DRD2 CNR1
25 regulation of dopamine uptake involved in synaptic transmission GO:0051584 9.49 DRD3 DRD2
26 negative regulation of dopamine receptor signaling pathway GO:0060160 9.48 DRD3 DRD2
27 response to histamine GO:0034776 9.46 DRD3 DRD2
28 regulation of locomotion involved in locomotory behavior GO:0090325 9.43 DRD3 DRD2
29 response to cocaine GO:0042220 9.43 DRD3 DRD2 CNR1
30 negative regulation of dopamine secretion GO:0033602 9.4 DRD2 CNR1
31 acid secretion GO:0046717 9.37 DRD3 DRD2
32 response to morphine GO:0043278 9.33 DRD3 DRD2 CNR1
33 negative regulation of blood pressure GO:0045776 9.13 DRD3 DRD2 CNR1
34 dopamine metabolic process GO:0042417 8.8 DRD3 DRD2 COMT

Molecular functions related to Polysubstance Abuse according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 G protein-coupled receptor activity GO:0004930 9.54 DRD3 DRD2 CNR1
2 adrenergic receptor activity GO:0004935 9.32 DRD3 DRD2
3 dopamine binding GO:0035240 9.26 DRD3 DRD2
4 dopamine neurotransmitter receptor activity, coupled via Gi/Go GO:0001591 9.16 DRD3 DRD2
5 dopamine neurotransmitter receptor activity GO:0004952 8.96 DRD3 DRD2
6 drug binding GO:0008144 8.8 DRD3 DRD2 CNR1

Sources for Polysubstance Abuse

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....